<i>Pcgf5</i>-deficient HSPCs retain normal reconstitution capacity of hematopoiesis.

<p>(A) Chimerism of donor-derived cells in recipients in competitive reconstitution assays using the same number of test cells (<i>Cre-ERT</i> and <i>Cre-ERT;Pcgf5</i>^<i>fl/fl</i>) and competitor cells. After engraftment, <i>Pcgf5</i> was deleted (<i>Pcgf5</i>^<i>Δ/Δ</i>) by tamoxifen injection. Data are shown as mean ± SD (n = 4–5). (B) Chimerism of donor-derived CD45.2⁺ hematopoietic cells in total BM cells, LSK cells, CLPs and myeloid progenitor fractions at 4 months post-transplantation. The data are shown as mean ± SD (n = 7). (C) Chimerism of donor-derived CD45.2⁺ cells in splenic LSK cells and donor-derived CD45.2⁺ thymocytes in the thymus at 4 months post-transplantation shown as mean ± SD (n = 3). (D, E) Secondary transplantation assays. Total BM cells (5x10⁶) from primary recipient mice at 4 months post-transplantation were transplanted into lethally irradiated secondary recipient mice without competitor cells. Chimerism of donor-derived cells in the PB (D) and total CD45.2⁺ hematopoietic cells and LSK cells in the BM (E) at 5 months post-transplantation are shown as mean ± SD (WT, n = 4; <i>Pcgf5</i>^<i>Δ/Δ</i>, n = 5). *<i>p</i><0.05; n.s., not significant.